Loading...
Loading...
VIGL| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.4M |
| Gross Profit | -0.4M |
| Operating Expense | 20.8M |
| Operating I/L | -20.8M |
| Other Income/Expense | 1.0M |
| Interest Income | 1.0M |
| Pretax | -19.8M |
| Income Tax Expense | -1.0M |
| Net Income/Loss | -18.8M |
Vigil Neuroscience, Inc. is a biopharmaceutical company specializing in the development of disease-modifying therapeutics for neurodegenerative diseases. Their lead product candidate, VGL101, is a monoclonal antibody designed to activate TREM2 and is in Phase I for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, cerebral adrenoleukodystrophy, and Alzheimer's disease. Additionally, the company is developing a small molecule TREM2 agonist for oral delivery to address common neurodegenerative diseases associated with microglial dysfunction.
